oral reversible covalent BTK inhibitor - Principia Biopharma (Sanofi), So. San Francisco, CA

oral reversible covalent BTK inhibitor

in Ph. III for immune thrombocytopenia

from structure-based drug design + opt.

J. Med. Chem.

Principia Biopharma (Sanofi), So. San Francisco, CA

Context. PRN1008 (rilzabrutinib, Sanofi) is an oral, reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor in a Ph. III trial for immune thrombocytopenia. A simultaneously published inhibitor, PRN473, is in…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.